الفهرس 
Introduction & Aim of studyOnly 14 pages are availabe for public view
 |  | from | 188 |  |  |
| | | from | 188 | | |
Abstract
Multiple myeloma (MM) is a cancer of terminally differentiated B-cells. Though new therapies have significantly improved the response rates as well as the survival among individuals with MM over the previous decade, it remains incurable in the majority of cases, and more effective therapeutic options are required. In malignant melanoma and hairy cell leukemia, targeting BRAF V600E mutation has been reported to have a clinical benefit. But, whether this also applies to cancers with a low frequency of such mutation is still not clear. The BRAF V600E mutation results in activation of Ras-Raf-MEK-ERK signaling pathway, stimulation of cellular growth, differentiation as well as survival. Such mutation has gained attention due to its potential for targeted inhibition. Aim of the study: The current study aimed to investigate the frequency and clinical features of BRAF V600E mutation in MM patients attending the Oncology Center Mansoura University and the association of BRAF V600E mutation with survival and well-established prognostic markers of MM cases. Conclusion: In this study, we found that BRAF V600E gene mutation is rare in MM patients and show female predominance . MM patients with positive mutant BRAF V600E gene show a significant decrease in overall survival and patient free survival. BRAF V600E mutation in MM patient shows a significant increase in serum creatinine and is considered a bad predictor for renal impairment.